COMMUNIQUÉS West-GlobeNewswire

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer
15/01/2026
The Science, Clinical Promise, & Market Outlook MELBOURNE, Australia, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on [...]
CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAIN
15/01/2026
TAIZHOU, China, Jan. 15, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (“China SXT” or the “Company”), a specialty pharmaceutical company focusing on the research, development, manufacturing, [...]
Adaptin Bio to Present at the 2026 Sequire Investor Summit in Puerto Rico
15/01/2026
CHARLOTTE, N.C., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Adaptin Bio , Inc. (“Adaptin” or the “Company”), a biotechnology company focused on developing precision cancer therapies with targeted delivery to the brain and other [...]
Precipio Takes Major Steps Toward a Clean Balance Sheet
15/01/2026
Less than $80,000 of long-term debt, and 10,000 vendor warrants remain outstanding NEW HAVEN, Conn., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has made major [...]
Phonak Virto R Infinio recognized in the 2026 BIG Innovation Awards for redefining custom hearing
15/01/2026
STÄFA, Switzerland, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Phonak , a global leader in innovative hearing solutions, today announced that Virto R Infinio has been named an Innovative Product Winner in the 2026 BIG Innovation [...]
Recommendation by the Orion Nomination Committee on the proposals to be presented to the 2026 Annual General Meeting
15/01/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 15 JANUARY 2026 at 16:30 EET Recommendation by the Orion Nomination Committee on the proposals to be [...]
14th Annual State of the Cure for T1D Shows Major Development in Cure Research
15/01/2026
NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Juvenile Diabetes Cure Alliance (JDCA), a 501(c)(3) nonprofit solely focused on accelerating a cure for type 1 diabetes, announced the release of the 14 th annual State of the [...]
Zelluna ASA: Approval and publication of prospectus
15/01/2026
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. [...]
Abpro’s Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference
15/01/2026
Recently IND-Cleared HER2 × CD3 T-Cell Engager Highlighted by Global Biopharmaceutical Partner BURLINGTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP), a clinical-stage biotechnology [...]
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
15/01/2026
NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced the first [...]
AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa
15/01/2026
This milestone marks significant progress in the first-in-human evaluation of AAVantgarde’s dual-AAV gene therapy designed to address the underlying cause of vision loss in patients with USH1B LONDON and MILAN, Jan. 15 [...]
Verano Announces Agreement to Upsize Revolving Credit Facility Commitment to $100,000,000 and Extend Maturity Date
15/01/2026
Amendment adds incremental $25,000,000 and extends maturity date from September 29, 2028 to February 28, 2029 CHICAGO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or [...]
Verdane Invests in Clue to Accelerate the Future of Women’s Health
15/01/2026
BERLIN, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Clue, the #1 women-led period and cycle tracker health and wellness app, with over 100 million downloads worldwide, today announced a significant and strategic investment from [...]
Digbi Health Publishes Peer-Reviewed Data Demonstrating Significant Cost Savings for Employers Via Its Precision Biology Telehealth Platform to Manage GLP-1, Metabolic, and GI Costs
15/01/2026
Actuarial claims analysis confirms up to 9X ROI across GLP-1, Metabolic, and GI Costs, demonstrating the power of gut microbiome and genetics-based biomarker care MOUNTAIN VIEW, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE [...]
Stablepharma and AFT Pharmaceuticals (NZX: AFT; ASX: AFP) partner to address multi-billion dollar anti-infective and oncology therapeutics market
15/01/2026
LONDON, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Stablepharma Limited, specialists in thermostable formulations, today announced a development and option-to-license agreement with AFT Pharmaceuticals to develop a portfolio of [...]
Santhera Receives Swissmedic Approval of AGAMREE® (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy
15/01/2026
Commercial launch in Switzerland anticipated in H2 2026 Pratteln, Switzerland, January 15, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces that the Swiss Agency for Therapeutic Products (Swissmedic), has approved [...]
Communiqué de presse : Myqorzo et Redemplo approuvés en Chine
15/01/2026
Myqorzo et Redemplo approuvés en Chine Approbation de Myqorzo pour la cardiomyopathie hypertrophique obstructive et de Redemplo pour le syndrome de chylomicronémie familiale. Souligne l’engagement à long terme de Sanofi [...]
Press Release: Myqorzo and Redemplo approved in China
15/01/2026
Myqorzo and Redemplo approved in China Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome Underscores Sanofi’s long-term commitment to China, reinforcing [...]
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
15/01/2026
NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation (reverse stock split) of [...]

Pages